Compare iShares Russell 2000 ETF (IWM) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs ResMed Inc. — how do they compare? iShares Russell 2000 ETF trades at $278.93 (market cap $77.70B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: iShares Russell 2000 ETF is far larger — about 2.4× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while iShares Russell 2000 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and ResMed Inc. for 51 Days on average.
| IWM | RMD | |
|---|---|---|
Market Cap | $77.70B | $31.89B |
Volume | 35,598,983 | 618,314 |
52-Week High | $305.06 | $275.96 |
52-Week Low | $229.13 | $182.82 |
Typical Hold Time | 83 Days | 51 Days |
Sector | — | Health |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM trades at $277.63, showing minimal daily movement with a slight decline of 0.03%. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, while oscillators remain neutral. The ETF faces headwinds from Federal Reserve rate hike concerns and underperformance relative to large-cap indices. Recent institutional selling and negative media coverage highlight ongoing challenges for small-cap exposure.
The outlook remains cautious as small-caps face pressure from tightening financial conditions and energy price volatility. While offering diversification from tech-heavy indices, IWM's inclusion of unprofitable companies and decade-long underperformance versus the S&P 500 present significant hurdles for near-term outperformance.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
